Imara cuts 83% of workforce, ends all pipeline programs, reviews strategic options

Enliven Therapeutics, Inc.

Workforce reduction of ~83% leaves only 6 full-time employees; substantially complete by Q2 2022.
Discontinues tovinontrine (IMR-687) in sickle cell, beta-thalassemia, and heart failure with preserved ejection fraction.
Also discontinues development of IMR-261; company starts comprehensive strategic review to maximize shareholder value.
One-time restructuring charge of $2.0-2.2 million expected in Q2 2022 for severance and benefits.
Chief Medical Officer Kenneth Attie, M.D. departs effective April 20, 2022.

item 2.0 item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Kenneth Attie

Chief Medical Officer

ELVN · Enliven Therapeutics, Inc.

Effective: 2022-04-20
Filed: April 14, 2022, 7:59 PM ET

Kenneth Attie, M.D., the Company’s Chief Medical Officer will separate from the Company effective April 20, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Kenneth Attie departed as Chief Medical Officer at Enliven Therapeutics, Inc..

Action: separated
Role: Chief Medical Officer

Exact text from the filing

Kenneth Attie, M.D., the Company’s Chief Medical Officer will separate from the Company effective April 20, 2022.

View on SEC.gov

Enliven Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-22-014494

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.